Drugs / coffee
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05692024 Comparator | Mar 2024 → Mar 2028 expected | colorectal cancer, fibrotic liver disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | coffee | “Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.” NCT05692024 ↗ |
| Route | Oral | “Treatment: Coffee or placebo administered daily, orally for 8-12 weeks.” NCT05692024 ↗ |